Invasive thymoma: Postoperative mediastinal irradiation, and low-dose entire hemithorax irradiation in patients with pleural dissemination

Journal of Thoracic Oncology

Volumn 3, Issue 1, 2008, Pages 75-81

  Sugie, Chikao ^a   Shibamoto, Yuta ^a   Ikeya Hashizume, Chisa ^a   Ogino, Hiroyuki ^a   Ayakawa, Shiho ^a   Tomita, Natsuo ^a   Baba, Fumiya ^a   Iwata, Hiromitsu ^a   Ito, Masato ^a   Oda, Kyota ^b  

^a NAGOYA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

^b Hokuto Hospital   (Japan)

Author keywords

Entire hemithorax radiotherapy; Invasive thymoma; Mediastinal radiotherapy; Pleural dissemination

Indexed keywords

ADULT; AGED; ARTICLE; CANCER INVASION; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; FEMALE; HUMAN; LOW ENERGY RADIATION; MAJOR CLINICAL STUDY; MALE; MEDIASTINUM; POSTOPERATIVE CARE; PRIORITY JOURNAL; PROGNOSIS; RADIATION DOSE FRACTIONATION; THYMOMA;

EID: 37549026517     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e31815e8b73     Document Type: Article

References (27)

1. Bretti S, Berutti A, Loddo C, et al. Multimodal management of stages III-IVa malignant thymoma. Lung Cancer 2004;44:69-77.
2. Kim ES, Putnam JB, Komaki R, et al. Phase II study of a multidisciplinary approach with induction chemotherapy, followed by surgical resection, radiation therapy, and consolidation chemotherapy for unresectable malignant thymomas: final report. Lung Cancer 2004;44:369-379.
3. Rena O, Papalia E, Maggi G, et al. World health organization histologic classification: an independent prognostic factor in resected thymomas. Lung Cancer 2005;50:59-66.
4. Masaoka A, Monden Y, Nakahara K, et al. Follow-up study of thymomas with special reference to their clinical stages. Cancer 1981;48:2485-2492.
5. Wilkins KB, Sheikh E, Green R, et al. Clinical and pathologic predictors of survival in patients with thymoma. Ann Surg 1999;230:562-574.
6. Strobel P, Bauer A, Puppe B, et al. Tumor recurrence and survival in patients treated for thymomas and thymic squamous cell carcinomas: a retrospective analysis. J Clin Oncol 2004;22:1501-1509.
7. Pollack A, Komaki R, Cox JD, et al. Thymoma: treatment and prognosis. Int J Radiat Oncol Biol Phys 1992;23:1037-1043.
8. Urgesi A, Monetti U, Rossi G, et al. Role of radiation therapy in locally advanced thymoma. Radiother Oncol 1990;19:273-280.
9. Uematsu M, Yoshida H, Kondo M, et al. Entire hemithorax irradiation following complete resection in patients with stage II-III invasive thymoma. Int J Radiat Oncol Biol Phys 1996;35:357-360.
10. Uematsu K, Kondo M. A proposal for treatment of invasive thymoma. Cancer 1986:1979-1984.
11. Ariaratnam LS, Kalnicki S, Mincer F, et al. The management of malignant thymoma with radiation therapy. Int J Radiat Oncol Biol Phys 1979;5:77-80.
12. Evans WK, Thompson DM, Simpson WJ, et al. Combination chemotherapy in invasive thymoma. Cancer 1980;46:1523-1527.
13. Zhu G, He S, Fu X, et al. Radiotherapy and prognostic factors for thymoma: a retrospective study of 175 patients. Int J Radiat Oncol Biol Phys 2004;60:1113-1119.
14. Bernatz PE, Harrison EG, Clagett OT. Thymoma: a clinicopathologic study. J Thorac Cardiovasc Surg 1961;42:424-444.
15. Kondo K, Yoshizawa K, Tsuyuguchi M, et al. WHO histologic classification is a prognostic indicator in thymoma. Ann Thorac Surg 2004;77:1183-1188.
16. Refaely Y, Simansky DA, Paley M, et al. Resection and perfusion thermochemotherapy: a new approach for the treatment of thymic malignancies with pleural spread. Ann Thorac Surg 2001;72:366-370.
17. Singhal S, Shrager JB, Rosenthal DI, et al. Comparison of stages I-II thymoma treated by complete resection with or without adjuvant radiation. Ann Thorac Surg 2003;76:1635-1641.
18. Rena O, Papalia E, Oliaro A, et al. Does adjuvant radiation therapy improve disease-free survival in completely resected Masaoka stage II thymoma? Eur J Cardiothorac Surg 2007;31:109-113.
19. Yokoi K, Matsunaga H, Nakahara R, et al. Multidisciplinary treatment for advanced invasive thymoma with cisplatin, doxorubicin, and methylprednisolone. J Thorac Oncol 2007;2:73-78.
20. Lucchi M, Melfi F, Dini P, et al. Neoadjuvant chemotherapy for stage III and IVA thymomas: a single-institution experience with a long follow-up. J Thorac Oncol 2006;1:308-313.
21. Loehrer PJ, Kim KM, Aisner SC, et al. Cisplatin plus doxorubicin plus cyclophosphamide in metastatic or recurrent thymoma: final results of an intergroup trial. J Clin Oncol 1994;12:1164-1168.
22. Lucchi M, Ambrogi MC, Duranti L, et al. Advanced stage thymomas and thymic carcinomas: results of multimodality treatments. Ann Thorac Surg 2005;79:1840-1844.
23. Allen AM, Czerminska M, Janne PA, et al. Fatal pneumonitis associated with intensity-modulated radiation therapy for mesothelioma. Int J Radiat Oncol Biol Phys. 2006;65:640-645
24. Yorke ED, Jackson A, Rosenzweig KE, et al. Correlation of dosimetric factors and radiation pneumonitis for non-small-cell lung cancer patients in a recently completed dose escalation study. Int J Radiat Oncol Biol Phys 2005;63:672-682.
25. Seppenwoolde Y, Lebesque JV, Jaeger KD, et al. Comparing different NTCP models that predict the incidence of radiation pneumonitis. Int J Radiat Oncol Biol Phys 2003;55:724-735.
26. Zhu XR, Prado K, Liu HH, et al. Intensity-modulated radiation therapy for mesothelioma: impact of multileaf collimator leaf width and pencil beam size on planning quality and delivery efficiency. Int J Radiat Oncol Biol Phys 2005;62:1525-1534.
27. Florino C, Dell'Oca I, Pierelli A, et al. Significant improvement in normal tissue sparing and target coverage for head and neck cancer by means of helical tomotherapy. Radiother Oncol 2006;78:276-282.